FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Kesha may now be a free and independent artist, but up until just a couple of years ago, she was contractually obligated to work with the same person she was suing on allegations of sexual assault.

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA ...

Topline data expected in H2 2026 LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ("Beacon Therapeutics" or "the Company"), a leading clinical-stage ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 1500 Health Care Index returned 5.5% in the first quarter, ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Surprised to hear us recommend pants your pops swears by? You shouldn’t be. In fact, their righteous, anti-fashion dadliness ...

This stunning yet haunting DC Comics Black Label series would be a perfect choice for the next streaming sensation!

President Donald Trump is reshaping a student loan cancellation program into what some fear will become a tool for political ...

Tividenofusp alfa is a novel central nervous system-penetrant enzyme replacement therapy designed to address the neurological manifestations of MPS II by delivering IDS into the brain and body.

The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...